Sung Lee - Mar 27, 2023 Form 4 Insider Report for Vir Biotechnology, Inc. (VIR)

Role
Chief Financial Officer
Signature
/s/ Vanina de Verneuil, Attorney-in-fact
Stock symbol
VIR
Transactions as of
Mar 27, 2023
Transactions value $
$0
Form type
4
Date filed
3/29/2023, 05:49 PM
Next filing
Feb 26, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction VIR Common Stock Award $0 +66.5K $0.00 66.5K Mar 27, 2023 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction VIR Stock Option (Right to Buy) Award $0 +133K $0.00 133K Mar 27, 2023 Common Stock 133K $23.01 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Acquisition of restricted stock units pursuant to the Issuer's Equity Incentive Plan.
F2 25% of the shares subject to the stock option vest and become exercisable on March 27, 2024, and the remainder vest in 36 equal monthly installments thereafter.